[Translation] A randomized, controlled, double-blind, double-dummy, multicenter clinical trial of Fufang Biejiaruangan Tablets [containing fermented Cordyceps sinensis powder (Cs-4)]

以原复方鳖甲软肝片（含冬虫夏草）为对照，评价发酵虫草菌粉（Cs-4）替代冬虫夏草后该品治疗慢性乙型肝炎肝纤维化、肝硬化的安全性和有效性。

[Translation]

To evaluate the safety and efficacy of the compound Biejiaruangan tablets (containing Cordyceps sinensis) in the treatment of liver fibrosis and cirrhosis caused by chronic hepatitis B after replacing Cordyceps sinensis with fermented Cordyceps sinensis powder (Cs-4) using the original compound Biejiaruangan tablets (containing Cordyceps sinensis) as a control.

Start Date-

Sponsor / Collaborator

Inner Mongolia Furui Medical Science Co., Ltd.

100 Clinical Results associated with Compound Biejia Ruangan Tablets

100 Translational Medicine associated with Compound Biejia Ruangan Tablets

100 Patents (Medical) associated with Compound Biejia Ruangan Tablets

Literatures (Medical) associated with Compound Biejia Ruangan Tablets

01 Feb 2015·Chinese Journal of Integrative MedicineQ3 · MEDICINE

Effects of Biejia Ruangan Tablet (复方鳖甲软肝片)-containing serum on matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in cultured renal interstitial fibroblasts

Q3 · MEDICINE

Article

Author: Shu-wen Liu ; Quan Hong ; Jin Zhou ; Xiang-mei Chen ; Bo Fu ; Shu-juan Wang

OBJECTIVETo investigate the effects of Biejia Ruangan Tablet ([symbol in text], BRT)-containing serum on the expression of matrix metalloproteinase (MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) in cultured renal interstitial fibroblasts.METHODSDifferent BRT-containing sera were prepared by gastric gavages to rats with the high-dose (7 g/kg), mid-dose (3.5 g/kg), and low-dose (1.75 g/kg) BRT respectively. The expression of extracellular matrix in NRK-49F cells was induced by treatment with human transforming growth factor-β1 (recombined human TGF-β1), and BRT-containing serum. Western blotting and Northern blotting were used to measure type I and III procollagen, MMP-9, and TIMP-1.RESULTSThe high dose BRT-containing serum could decrease the type I and III procollagen gene expression which boosted by TGF-β1, at the same time cut down TIMP-1 protein and gene expression which increased by TGF-β1 (P <0.05). Treatment of cells with recombined human TGF-β1 had no significant effect on MMP-9 expression and BRT-containing serum also had no effect on MMP-9 expression.CONCLUSIONSHigh dose BRT has anti-fibrosis effects in NRK-49F cells, as indicated by its inhibition of type I and III procollagen and TIMP-1 expression.

15 Nov 2007·Journal of Chinese Integrative Medicine

Effect of compound Biejia Ruangan tablet on expressions of connective tissue growth factor mRNA and protein in kidney tissue of rats with adriamycin-induced nephropathy

Article

Author: Zhang, Xin-xue ; Qiu, Qi ; Zhao, Zong-jiang ; Yang, Mei-juan

OBJECTIVETo investigate the changes of connective tissue growth factor (CTGF) protein and CTGF mRNA in kidney tissue of rats with adriamycin (ADR)-induced nephropathy and to study the effects of compound Biejia Ruangan tablet (CBJRGT), a traditional Chinese herbal medicine for treatment of liver fibrosis.METHODSA rat model of ADR-induced nephropathy after one-sided nephrectomy was established. Forty-five Wistar rats were randomly divided into 5 groups: normal control group, sham-operated group, untreated group, lotensin-treated group and CBJRGT-treated group. Pathological changes of the kidney tissue were observed by microscopy after 10-week drug administration. The expressions of CTGF protein and CTGF mRNA in the kidney tissue were measured by the methods of immunohistochemistry and in situ hybridization.RESULTSThe expressions of CTGF protein and CTGF mRNA in the normal and sham-operated groups were decreased in the intracytoplasm of glomerular mesangial cells, renal tubular epithelial cells and interstitial cells. Compared with the sham-operated group, the expressions of CTGF protein and CTGF mRNA in the untreated group were markedly increased and the development of renal fibrosis in the untreated group could be observed. CBJRGT could significantly decrease the expressions of CTGF protein and CTGF mRNA, and there was no significant difference between CBJRGT-treated group and lotensin-treated group.CONCLUSIONCBJRGT may suppress the development of fibrosis through down-regulating the expressions of CTGF protein and CTGF mRNA.

100 Deals associated with Compound Biejia Ruangan Tablets

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Liver Cirrhosis	China	Inner Mongolia Furui Medical Science Co., Ltd.	15 Apr 2020

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Fibrosis, Liver	Phase 3	China	Inner Mongolia Furui Medical Science Co., Ltd.	13 Feb 2014
Hepatitis B, Chronic	Phase 3	China	Inner Mongolia Furui Medical Science Co., Ltd.	13 Feb 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Compound Biejia Ruangan Tablets

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation